KRK Stock Overview
A generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Krka, d. d. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €744.00 |
| 52 Week High | €776.00 |
| 52 Week Low | €524.00 |
| Beta | 0.50 |
| 1 Month Change | 5.38% |
| 3 Month Change | 16.61% |
| 1 Year Change | 35.27% |
| 3 Year Change | 80.15% |
| 5 Year Change | 115.65% |
| Change since IPO | 254.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| KRK | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | 2.5% | -1.3% | 6.8% |
| 1Y | 35.3% | 30.8% | 8.4% |
Return vs Industry: KRK exceeded the Polish Pharmaceuticals industry which returned 30.8% over the past year.
Return vs Market: KRK exceeded the Polish Market which returned 8.4% over the past year.
Price Volatility
| KRK volatility | |
|---|---|
| KRK Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in PL Market | 11.5% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: KRK has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: KRK's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 11,308 | Jože Colaric | www.krka.biz |
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company’s prescription pharmaceuticals include medicines for the treatment of cardiovascular, gastrointestinal tract and metabolism, central nervous system, infections, oncology, and other diseases. It provides non-prescription products for oral cavity and pharynx; cough and cold; analgesics; nasal products; vitamin and mineral products; products for enhancing cerebral and peripheral circulation; products for enhancing digestive tract and digestion; health care products; and others.
Krka, d. d. Fundamentals Summary
| KRK fundamental statistics | |
|---|---|
| Market cap | zł22.47b |
| Earnings (TTM) | zł1.53b |
| Revenue (TTM) | zł8.18b |
14.8x
P/E Ratio2.8x
P/S RatioIs KRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KRK income statement (TTM) | |
|---|---|
| Revenue | €1.91b |
| Cost of Revenue | €815.66m |
| Gross Profit | €1.09b |
| Other Expenses | €736.90m |
| Earnings | €356.99m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 15, 2025
| Earnings per share (EPS) | 11.67 |
| Gross Margin | 57.29% |
| Net Profit Margin | 18.69% |
| Debt/Equity Ratio | 0% |
How did KRK perform over the long term?
See historical performance and comparisonDividends
4.3%
Current Dividend Yield64%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/17 20:26 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Krka, d. d. is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Saso Stanovnik | Alta Invest |
| Simon Mather | Barclays |
| Stephane Sumar | BNP Paribas Exane |